The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen- binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.
